Physician profile
William Shaffer
NPI 1972506913
$1,762.14
in general payments reported to CMS, 2019-2025
18 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $120 · 2021: $293 · 2022: $335 · 2023: $233 · 2024: $331 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.28 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $448.00 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $263.08 | 2021-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $193.99 | 2021-2023 | Krystexxa |
| Amgen INC. | $180.70 | 2020-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $125.41 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $112.99 | 2019 | |
| Calliditas Therapeutics US INC. | $75.68 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $60.26 | 2020-2022 | |
| Travere Therapeutics, INC. | $46.43 | 2022 | |
| Opko Pharmaceuticals, LLC | $42.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.98 | 2023-2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $37.30 | 2021 | |
| Fresenius USA Marketing, INC. | $30.76 | 2019-2020 | |
| Medtronic, INC. | $27.92 | 2025 | Symplicity G3 |
| Vifor Pharma, INC. | $22.40 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.43 | 2025 | Shingrix, Arexvy |
| Cormedix INC. | $19.99 | 2025 | Defencath |
| Novo Nordisk INC | $15.27 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.